肿瘤细胞治疗研究
英文原题：Immunotherapy in gastric adenocarcinoma - a rapidly evolving treatment landscape.
胃癌（GC）是全球诊断排名第五的常见癌症。
胃癌（GC）是全球第五大常见癌症。尽管治疗有所进步，患者预后仍较差。免疫检查点抑制剂已越来越多地用于GC和胃食管结合部（GEJ）腺癌的各个治疗阶段，包括可切除早期G/GEJ癌的围手术期治疗，以及转移性疾病中的化疗和靶向药联合治疗。本综述旨在总结GC分子亚型，概述免疫疗法用于早期和晚期疾病的关键证据，并讨论GC生物标志物和新型免疫疗法。
Gastric cancer (GC) ranks as the fifth most common cancer diagnosed worldwide. Despite advances in treatment, the prognosis for patients remains poor. Immune checkpoint inhibitors have been increasingly utilised across all settings in the treatment of GC and gastroesophageal junction (GEJ) adenocarcinomas; from perioperative treatment of resectable early-stage G/GEJ cancers to combination with chemotherapy and targeted agents in metastatic disease. This review aims to summarise the molecular subtypes of GC, outline the key evidence for the use of immunotherapy in early and advanced stage settings and discuss biomarkers and novel immunotherapeutics for GC.
MEMBER ACCOUNT
登录成功会直接打开下一页。
